ArticleiScience2023

Tocilizumab-treated convalescent COVID-19 patients retain the cross-neutralization potential against SARS-CoV-2 variants.

Camille Chauvin et al.PubMed ↗Full text ↗Publisher ↗

No numbers read from the abstract.